首页> 美国卫生研究院文献>Radiation Oncology Journal >Less is more: role of additional chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal cancer management
【2h】

Less is more: role of additional chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal cancer management

机译:少即是多:在局部晚期鼻咽癌管理中附加化学疗法在同时放化疗中的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Concurrent chemoradiation therapy (CCRT) has played the most important and central role in the definitive therapy for the patients with locoregionally advanced stage nasopharynx cancer. The addition of induction chemotherapy (IC) or adjuvant chemotherapy (AC) to CCRT have been widely accepted with the rationale of improving distant control in the clinical practices. This review article investigated the role of IC and AC based on 11 recent meta-analysis publications, and found that the clinical benefits obtained by the additional IC or AC to CCRT, at the cost of the increased risks of more frequent and more severe side effects, seemed not big enough. More intervention is not always better, however, less seems frequently good enough. The author would speculate that ‘less is more’ and would advocate CCRT alone as the current standard.
机译:并行化学放疗(CCRT)在局部晚期鼻咽癌患者的最终治疗中起着最重要和最重要的作用。 CCRT上增加诱导化疗(IC)或辅助化疗(AC)已被广泛接受,其理由是改善临床实践中的远程控制。这篇综述文章基于11篇最近的荟萃分析出版物研究了IC和AC的作用,并发现以CCRT额外添加IC或AC可获得临床益处,但增加了更频繁和更严重的副作用的风险,似乎还不够大。进行更多的干预并不总是总能带来更好的效果,但是,减少干预似乎常常是足够好的。作者将推测“少即是多”,并主张仅将CCRT作为当前标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号